Hot Biotech Companies To Invest In Right Now: Incyte Corporation(INCY)
Incyte Corporation focuses on the discovery and development of proprietary small molecule drugs for hematologic and oncology indications, and inflammatory and autoimmune diseases. Its product pipe line includes INCB18424, which is in Phase III clinical trial for myelofibrosis; Phase III trial for polycythemia vera; Phase III trial for essential thrombocythemia; Phase I/II trial to treat solid tumors/other hematologic malignancies; and Phase IIb trail for the treatment of psoriasis. The company?s portfolio also includes INCB28050, a Phase IIb clinical trial product for rheumatoid arthritis; INCB28060, a Phase I/II product for solid tumors; INCB7839, a Phase II product for breast cancer; and INCB24360, a Phase I/II product for solid tumors. It has a collaborative research and license agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; and Pfizer Inc. The company was founded in 1991 and is headquartered in Wilmington, Delaware.
Advisors' Opinion:- [By John McCamant]
Incyte Pharmaceuticals (INCY) recently held their quarterly conference call. Importantly, sales for Jakafi—an advanced compound used for the treatment of patients with intermediate or high-risk myelofibrosis (MF)—met or exceeded Wall Street's expectations.
- [By Ben Levisohn]
Sure Intercept Pharmaceuticals (ICPT) might feel like the only biotech stock that matters today, but there are others. For instance, Incyte (INCY) and BioMarin (BMRN) are on the move after Barclays changed its ratings on the pair.
- [By Ben Levisohn]
Somaiya and team named Gilead and Neurocrine Biosciences (NBIX) their top picks, hile putting Buy ratings on Celgene, Biogen Idec, Alexion (ALXN), Incyte (INCY), Pharmacyclics (PCYC) and Synageva (GEVA). BioMarin (BMRN), Infinity Pharmace! uticals (INFI) and Amgen (AMGN) earned Neutral ratings.
source from Top Stocks Blog:http://www.topstocksblog.com/hot-biotech-companies-to-invest-in-right-now.html
No comments:
Post a Comment